Spatial and Temporal Regulation of Focal Adhesion Kinase Activity in Living Cells by Cai, X. et al.
MOLECULAR AND CELLULAR BIOLOGY, Jan. 2008, p. 201–214 Vol. 28, No. 1
0270-7306/08/$08.000 doi:10.1128/MCB.01324-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Spatial and Temporal Regulation of Focal Adhesion Kinase Activity in
Living Cells
Xinming Cai,1 Daniel Lietha,5 Derek F. Ceccarelli,5† Andrei V. Karginov,2 Zenon Rajfur,1
Ken Jacobson,1,3 Klaus M. Hahn,2,3 Michael J. Eck,5 and Michael D. Schaller1,3,4*
Department of Cell and Developmental Biology,1 Department of Pharmacology,2 Lineberger Comprehensive Cancer Center,3 and
Carolina Cardiovascular Biology Center,4 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, and
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 021155
Received 23 July 2007/Returned for modification 21 August 2007/Accepted 22 October 2007
Focal adhesion kinase (FAK) is an essential kinase that regulates developmental processes and functions in
the pathology of human disease. An intramolecular autoinhibitory interaction between the FERM and catalytic
domains is a major mechanism of regulation. Based upon structural studies, a fluorescence resonance energy
transfer (FRET)-based FAK biosensor that discriminates between autoinhibited and active conformations of
the kinase was developed. This biosensor was used to probe FAK conformational change in live cells and the
mechanism of regulation. The biosensor demonstrates directly that FAK undergoes conformational change in
vivo in response to activating stimuli. A conserved FERM domain basic patch is required for this conforma-
tional change and for interaction with a novel ligand for FAK, acidic phospholipids. Binding to phosphati-
dylinositol 4,5-bisphosphate (PIP2)-containing phospholipid vesicles activated and induced conformational
change in FAK in vitro, and alteration of PIP2 levels in vivo changed the level of activation of the conforma-
tional biosensor. These findings provide direct evidence of conformational regulation of FAK in living cells and
novel insight into the mechanism regulating FAK conformation.
Focal adhesion kinase (FAK) is an essential non-receptor
tyrosine kinase, since FAK-null mice exhibit embryonic lethal-
ity (21). In endothelial cells, FAK is required for the proper
development of the vasculature (5, 51), and in neurons FAK
regulates netrin-mediated axon outgrowth and dendrite forma-
tion (41, 45). In addition to these roles in development, FAK
is also implicated in the pathology of disease. FAK expression
is required in cardiomyocytes to promote hypertrophy and
fibrosis in response to cardiac stress and potentially plays a role
in the development of heart disease (18, 42). Overexpression of
FAK is observed in many types of cancer (22), and experiments
using animal models have implicated FAK in tumor formation
and metastasis in a number of neoplasms, including cancer of
the brain, breast, and skin (38, 39, 58).
Despite the importance of FAK in controlling multiple de-
velopmental and pathological events, the molecular mecha-
nism of regulation remains incompletely elucidated. Like many
kinases posttranslation modification, particularly phosphoryla-
tion, is a major regulatory mechanism. Tyrosine 397 is the
major site of autophosphorylation, and mutation of this site
abrogates the biological activity of FAK (47). This site primar-
ily serves a scaffolding function, providing a docking site for a
number of proteins containing SH2 domains, including Src and
phosphatidylinositol 3-kinase (47). The interaction with FAK
occupies both the SH2 and SH3 domains of Src preventing
intramolecular inhibitory interactions resulting in stabilization
of Src in its active conformation (54). Complex formation also
serves to direct Src to its substrates, which include FAK itself.
Activated Src phosphorylates FAK on multiple sites, including
two tyrosine residues in the activation loop, Y576 and Y577,
which function in regulating catalytic activity (6).
A number of protein-protein interactions also regulate FAK
activity. FIP200 is a negative regulator of kinase activity (57).
The interaction of FIP200 with FAK is complex, with multiple
FIP200 binding sites in FAK (1). This complex dissociates
upon cell adhesion, which is a stimulus leading to FAK acti-
vation (1). The interaction of FAK with growth factor recep-
tors positively regulates FAK signaling. Stimulation of fibro-
blasts promotes FAK binding to the epidermal growth factor
(EGF) and platelet-derived growth factor (PDGF) receptors,
which is required for EGF- and PDGF-induced chemotaxis
(52). Stimulation of cells with hepatocyte growth factor (HGF)
promotes the direct association of FAK with the Met receptor,
and this interaction is required for HGF induced activation of
FAK (14). A potential ligand-binding site within the N-termi-
nal domain of FAK, consisting of a series of basic residues, is
required for maximal activation of FAK and subsequent down-
stream signaling following cell adhesion to fibronectin (20).
The same site forms the binding site for tyrosine-phosphory-
lated Met receptor (14), and thus this sequence is required for
activation of FAK in response to diverse stimuli.
Multiple studies support a model of regulation whereby the
FAK FERM domain interacts with the FAK catalytic domain
to impair catalytic activity in the inactive state. Truncation of
the FERM domain increases FAK tyrosine phosphorylation
and/or kinase activity (11, 27, 48, 49, 56). Further, the FERM
domain can interact in trans with the catalytic domain in vivo
and inhibit its activity (16). Mutation of K38 within the FERM
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domain disrupts the FERM/kinase domain interaction, and
when introduced into the full-length molecule activates FAK
(15). The molecular details of the FERM-catalytic domain
interaction were revealed by X-ray crystallography (32). In this
complex, the FERM domain blocks the active site of the kinase
domain inhibiting access to the ATP and substrate binding
sites. Further, the activation loop lies within the cleft between
the FERM and kinase domains. These studies support a model
of FAK activation entailing a switch from autoinhibited to
active conformation, however, the challenging task of testing
this model under physiological conditions in living cells has yet
to be undertaken.
In this paper, we report the development of two biosensors
that can measure two important facets of FAK activation in
live cells: (i) phosphorylation of Y397, which reflects a FAK
scaffolding function; and (ii) a conformational change associ-
ated with FAK activation. The novel conformational biosensor
directly demonstrates that a conformation change in FAK oc-
curs in living cells upon FAK activation. The biosensor was
further used to probe the spatial regulation of FAK and mech-
anisms involved in controlling conformation changes. Acidic
phospholipids are identified as novel ligands for FAK. Phos-
phatidylinositol 4,5-bisphosphate (PIP2)-containing vesicles al-
ter FAK conformation in vitro and modulating PIP2 levels
alters FAK conformation in vivo. These findings support the
model that FAK is regulated via interaction with lipid ligands
and provide mechanistic insight into the observation that acidic
phospholipids are required for FAK activation (7, 28, 34, 36).
MATERIALS AND METHODS
Cell culture. 293T cells were maintained in Dulbecco’s modified Eagle’s me-
dium (DMEM) F-12 medium containing 10% fetal bovine serum (FBS) and
HeLa cells in DMEM containing 10% FBS. Cells were transfected using Lipo-
fectamine Plus (Invitrogen) according to manufacturer’s instructions. HeLa cells
were starved in DMEM overnight prior to stimulation with ligands. To measure
adhesion-dependent activation cells were maintained adhered to substrate or
incubated in suspension at 37°C for 1 h prior to lysis.
Molecular biology. To generate CFAK, the full-length FAK cDNA was in-
serted into the enhanced cyan fluorescent protein (CFP) construct ECFP-C1, in
frame with CFP. Citrine was generated from the enhanced yellow fluorescent
protein (YFP) construct EYFP-C1 vector by mutation of glutamine 69 to me-
thionine (25). To generate citrine-dSH2, two Src SH2 domains were sequentially
introduced into the citrine construct. This was achieved by PCR amplification of
the c-Src SH2 domain (positions 553 to 894) and insertion of two copies of the
SH2 coding sequence between the XhoI and PstI sites within citrine vector. To
generate FAK conformation probes, six-nucleotide insertions encoding a NotI
site were introduced into different sites of CFAK. Citrine was amplified with
primers containing NotI sites, and the PCR product was introduced into the NotI
site within CFAK. All mutations were generated by the QuickChange mutagen-
esis strategy. The full-length constructs were analyzed by sequencing to verify the
intended mutations and ensure that no unintended mutations were present. The
expression construct for PIPKI was the generous gift of Richard Anderson
(University of Wisconson) and a YFP-SopB construct was a generous gift of
Jorge Galán (Yale University). For this study, the SopB encoding sequences
were amplified by PCR and subcloned into pcDNA3.1.
Fluorometric measurements of FRET. For live-cell fluorometric measure-
ments of fluorescence resonance energy transfer (FRET), 293 cells expressing
different constructs were typsinized and suspended in phosphate-buffered saline
(PBS). The cells were analyzed using a Fluorolog SPEX 168 fluorometer or a
spectrofluorophotometer RF-1501 (Shimadzu). The cell suspension was excited
at 425 nm, and an emission scan was acquired from 450 to 550 nm. The spectra
of different samples in a single experiment were normalized to CFP emission of
a reference spectrum.
Measuring FRET by microscopy. HeLa cells expressing biosensors were plated
on fibronectin (5 g/ml [Sigma])-coated coverslips (Lucas Highland). After in-
cubation at 37°C for 1 h, the cells were transferred to the microscope’s heated
chamber (Warner Instrument Corporation TC-344B) in Ham’s F-12 K medium
without phenol red (Biosource), 25 mM HEPES (pH 7.4), and 5% FBS. Images
were collected using a Zeiss 100 1.3-numerical aperture lens, a Zeiss Axiovert
100TV microscope, a Cool Snap ES digital camera, and Metamorph software
(Universal Imaging). The filters and dichroic mirror setting for FRET images
were as follows: (i) CFP, D436/20 and D470/40; (ii) FRET, D436/20 and HQ535/
30; and (iii) YFP, HQ500/20 and HQ535/30 (44). The CFP, FRET, and YFP
images were recorded using 2  2 binning. For ligand stimulation, transfected
HeLa cells were serum starved overnight, transferred to the microscope’s heated
chamber, and imaged, before and after ligand stimulation, in Hank’s balanced
salt solution buffer with 20 mM HEPES (pH 7.4) and 2 g/liter glucose. At each
time point, images were collected using a Zeiss 40 1.3-numerical aperture Plan
NeoFluor lens and 4  4 binning.
For photobleaching assays, HeLa cells expressing the FAK biosensor were
illuminated to excite CFP and imaged in both the CFP and FRET channels at
11-s intervals. The YFP acceptor was photobleached by pulse illumination for 6 s
at each 11-s interval. The mean intensity from the whole cell was measured at
each time point and normalized to the zero time point at the initiation of
photobleaching. For laser-scanning confocal microscopy, 293 cells expressing the
donor (CFAK), acceptor (citrine-dSH2), or both were analyzed. Images were
recorded using a LSM 510 laser-scanning confocal microscope (Zeiss) in lambda
stack mode. For photobleaching, the cells were photobleached at 488 nm. The
emission spectra following stimulation at 458 nm were recorded before and after
photobleaching.
Image processing and analysis. Images were processed as previously described
(10, 13, 29, 44). CFP, FRET, and citrine images were background subtracted and
registered. For the FAK conformation biosensor, the background subtracted
CFP image was divided by the background subtracted FRET image to get a
pixel-to-pixel CFP/FRET ratio image. The CFP images were thresholded to
generate a binary mask with a value of 0 outside the cell and a value of 1 inside
the cell. The CFP/FRET ratio images were multiplied with the mask and dis-
played in pseudocolors scaled from the lowest to the highest signal within the
cell, eliminating pixels outside the 5 to 95% range on the intensity histogram, to
provide a more reasonable estimate of the biosensor’s useful dynamic range. For
the FAK autophosphorylation biosensor, the images were processed with the
equation FRETC  FRET  (a  CFP)  (b  citrine) (59), where FRETC is
corrected FRET, a is the percentage of CFP bleed through (determined from
cells expressing only CFP-FAK), and b is the percentage of citrine bleed through
(determined from cells expressing only expressing citrine-dSH2).
To quantify the focal adhesion and cytoplasm FRET values, two segmented
images were generated using a threshold function. Two segmented images were
used to generate binary masks for focal adhesions and the cytoplasm. The FRET
ratio images were multiplied with the two masks to generate the ratio images for
focal adhesions and cytoplasm. To determine the relationship between focal
adhesion FRET value and distance to the cell margin, the focal adhesion binary
mask was used to generate an individual segmented region around each focal
adhesion. The segmented regions for focal adhesions were loaded to the focal
adhesion CFP/FRET ratio image. The individual focal adhesion parameters,
including average intensity and x and y values of each focal adhesion, were
exported to Excel to generate a focal adhesion database. The cell margin was
plotted based on the registered CFP image and transformed to a set of x and y
values using Image J. The set of margin x and y values were imported into Excel.
The minimal margin distance was measured by determining the minimal value
ofx1  x22  y1  y22, where x1 and y1 are the coordinates of each focal
adhesion and x2 and y2 are the coordinates of each point at the margin of
the cell.
Lipid binding assays. Lipid vesicles were prepared by mixing chloroform-
dissolved phospholipids (Avanti Polar Lipids) in the appropriate ratios keeping
the PE/PC mass ratio as 3:1, while other lipids were supplemented to the final
concentration indicated. The mixture was dried using a speed vacuum for 15 min.
The dried lipid mixture was suspended and sonicated in lipid binding buffer (40
mM HEPES [pH 7.5], 2 mM dithiothreitol,150 mM NaCl) to a final concentra-
tion of 2.5 g/l. For cosedimentation, 4 g of glutathione S-transferase (GST)
fusion protein was incubated with 250 g of lipid vesicles on ice for 1 h. The
mixtures were subsequently centrifuged at 110,000  g for 1 h at 4°C. The
supernatants were collected. The pellets were suspended in 100 l sodium
dodecyl sulfate (SDS) buffer and boiled for 2 min to dissolve. Both the super-
natants and pellets were mixed with Laemmli sample buffer and boiled for 5 min.
The samples were analyzed by SDS-polyacrylamide gel electrophoresis (PAGE)
and Coomassie blue staining. For fluorescence polarization, the purified FERM
domain (9) was incubated with BODIPY (dipyrromethene boron difluoride)-
labeled phosphoinosotides with C6-acyl chains (8). Increasing concentrations of
purified protein was added to 12.5 nM fluorescent phosphoinositide in buffer
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containing 20 mM HEPES [pH 7.0], 150 mM NaCl, and 5 mM 	-mercapto-
ethanol. Anisotropy measurements were taken at 21°C using a Beacon 2000
fluorescence polarization instrument. Binding curves and dissociation constants
were determined using the program Prism (GraphPad Software Inc.).
Protein purification and kinase assay. The GST-fusion proteins were induced
and purified as previously described (20, 37). For immune complex kinase assays,
FAK and its variants were immunoprecipitated using the BC4 polyclonal anti-
serum or green fluorescent protein (GFP) antibody and the immune complexes
incubated with 2 g of GST–paxillin–N-C3 using previously described kinase
reaction conditions (37). The reaction was terminated by the addition of sample
buffer and phosphorylation of paxillin examined by Western blotting.
Expression of the recombinant fragment of FAK containing the FERM and
catalytic domains has been described previously (32). For in vitro kinase assays
using recombinant proteins, 200 ng of the recombinant FAK fragment and 1 g
Src (SH3 plus SH2 plus kinase) were incubated with liposomes in kinase reaction
buffer (100 mM Tris [pH 7.5], 100 mM MgCl2, 50 M ATP) for 30 min. The
reaction was terminated by the addition of sample buffer, and phosphorylation of
recombinant FAK was examined by Western blotting.
Protein analysis. Cells were lysed in ice-cold modified radioimmunoprecipitation
assay buffer. Lysates were clarified, and protein concentrations were determined
using the bicinchoninic acid assay (Pierce, Rockford, IL). Immunoprecipitations
were performed using a polyclonal FAK antibody (BC4) or a GFP monoclonal
antibody (Roche). For Western blotting, the FAK antibody (447) and phosphoty-
rosine antibody (4G10) were from Millipore, the PY576 antibody was from Bio-
source, and the paxillin polyclonal antibody was previously described (53).
RESULTS
Development of a FAK autophosphorylation biosensor. Ty-
rosine 397 is the major FAK autophosphorylation site, which is
critical for FAK function and serves as a scaffolding site to
recruit other proteins into complex. To visualize FAK auto-
phosphorylation status in living cells, a genetically encoded
FRET-based biosensor was developed. As a similar biosensor
has been described (4), it will only be briefly introduced. CFP
was fused to the FAK N terminus to serve as the FRET donor
and citrine, a variant of YFP, was fused to two Src SH2 do-
mains to serve as the FRET acceptor (Fig. 1A). Since phos-
phorylation of tyrosine 397 regulates Src SH2 domain binding
to this site, CFAK should only interact with citrine-dSH2 and
produce a FRET signal when the former is phosphorylated at
tyrosine 397. The interaction between CFAK and citrine-dSH2
was confirmed by coimmunoprecipitation (X. Cai and M. D.
Schaller, unpublished data). Citrine-dSH2, but not citrine
alone, coimmunoprecipitated with CFAK, and this interaction
was abolished when tyrosine 397 in CFAK was substituted for
with phenylalanine. Upon coexpression in 293 cells, CFAK and
citrine-dSH2 colocalized peripherally near the membrane (Cai
and Schaller, unpublished). In contrast, CFAK-Y397F and cit-
rine dSH2 were not colocalized. These data demonstrate that
the interaction between CFAK and citrine-dSH2 depends
upon phosphorylation of tyrosine 397. FRET was measured in
several ways. Initially, cells were scraped from the tissue cul-
ture dish and FRET was measured in cells in suspension using
a fluorometer. These measurements were made rapidly upon
removing the cells from the dish (within 10 min), before exog-
enously expressed FAK could be inactivated and dephosphor-
ylated. No FRET signal was detected in 293 cells expressing
CFAK or citrine-dSH2 alone, whereas a strong FRET signal
was detected in cells coexpressing both proteins (Fig. 1B).
Notably, no FRET signal was detected in cells coexpressing
CFAK-Y397F and citrine-dSH2. Note that similar results were
obtained when adherent cells were lysed and the lysates, rather
than suspended cells, were analyzed (Cai and Schaller, unpub-
lished). Expression levels of the wild type and mutant biosen-
sor were comparable (Cai and Schaller, unpublished data).
FRET was also measured microscopically. As a further con-
trol, acceptor photobleaching was used to validate the FRET
signal in vivo. HEK293 cells coexpressing CFAK and citrine-
dSH2 were photobleached using an argon laser (488 nm). A
series of fluorescent images were collected by laser-scanning
confocal microscopy, and the average pixel intensity of the
photobleached area at the CFP and FRET emission wave-
lengths was determined. As shown in Fig. 1C, photobleaching
the FRET acceptor resulted in a decrease in the acceptor
signal and an increase in the CFP donor signal, which was
caused by the interruption of energy transfer from CFAK to
citrine-dSH2.
Development of a FAK conformational biosensor. The struc-
ture of the FERM/catalytic domain complex confirms the role
of the FERM domain in autoinhibition of catalytic activity and
suggests that a transition from the autoinhibitory conformation
to an open, active conformation is a required step for FAK
activation. A FRET-based FAK probe was developed to mon-
itor such a conformational change in living cells. As shown in
Fig. 2A and B, CFP was fused in the N terminus of FAK and
citrine was inserted into the linker between the FERM and
catalytic domains to generate the CYFAK413 biosensor. As a
control, citrine was inserted at the C terminus of the catalytic
domain to generate the CYFAK700 construct. The emission
spectrum of these constructs following stimulation with the
CFP excitation wavelength was determined using a fluorome-
ter. Again, measurements were made rapidly after taking the
cells into suspension and similar results were found using ly-
sates from adherent cells. A strong FRET peak was detected in
cells expressing CYFAK413 (Fig. 2C). In contrast a very weak
FRET signal was detected in cells expressing CFAK700. Co-
expression of CFAK and YFAK, in which the CFP and citrine
are presented in trans, did not yield a FRET signal in this assay.
In addition to the fluorometer assay, CYFAK413 was charac-
terized by microscopy and FRET was validated by acceptor
photobleaching. Upon photobleaching, the citrine intensity de-
creased and the CFP signal increased, confirming that FRET
was occurring (Fig. 2D). The 12% increase in CFP signal upon
acceptor photobleaching is similar to that reported for the
vinculin conformation biosensor (13).
To test whether the FRET signal of CYFAK413 was regu-
lated by conformational change, mutational studies were per-
formed. The major contacts between the FERM and catalytic
domains are centered around F596 of the catalytic domain,
which binds in a hydrophobic pocket on the FERM domain
(Fig. 2E). Mutation of Y180 and M183, which form part of the
hydrophobic pocket of the FERM domain, results in activation
of FAK in vitro and in vivo (32). These activating mutations
were engineered into CY413FAK, and as shown in Fig. 2F, this
mutant showed reduced FRET compared to the wild-type
probe. In addition to this mutant, other activating mutations
that disrupt the FERM/catalytic domain interaction were also
introduced into the FAK conformational probe (Fig. 2G).
Each of these mutants also exhibited a low FRET/CFP ratio
compared with the wild-type probe. The expression of these
mutant biosensors was comparable to that of the wild-type
biosensor (Cai and Schaller, unpublished). These findings
demonstrate that the FRET signal of this biosensor depends
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FIG. 1. (A) Design of the FAK autophosphorylation biosensor. When tyrosine 397 is unphosphorylated, CFAK does not interact with
citrine-dSH2 and FRET does not occur. When tyrosine 397 is phosphorylated, CFAK interacts with citrine-dSH2 and FRET occurs. (C, CFP; Y,
citrine). (B) The FAK wild-type autophosphorylation biosensor and the CFAK-Y397F control biosensor were expressed in HEK293 cells and
analyzed by fluorometry. CFP was selectively excited at 425 nm, and the resulting emission spectra were normalized to the CFP emission peak.
(C) FRET in the FAK biosensor was verified by acceptor photobleaching in living cells. HEK293 cells were photobleached using a 488-nm laser.
The emission spectra produced by CFP excitation were recorded before and after photobleaching. Shown are the average results from three
experiments 
 standard error.
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FIG. 2. (A) Design of the FAK conformation biosensor (CYFAK413). In the inactive conformation, the CFP and citrine are in proximity and
FRET occurs. In the open conformation, the CFP and citrine are further apart and can rotate more freely, which will result in a reduced FRET
signal. (B) Schematic structure of the FAK biosensor and control biosensors. CFP is fused to the N terminus. The numbers in the construct name
refer to the citrine insertion site. (C) Normalized spectra of the FAK wild-type biosensor and control biosensors were measured by fluorometry.
(D) FRET in the FAK conformation biosensor was verified by acceptor photobleaching in living cells. HeLa cells expressing the biosensor were
imaged in both CFP and citrine channels following excitation of CFP at 11-s intervals. The acceptor (citrine) was photobleached by pulse
illumination for 6 s at each 11-s interval, after the zero time point. The mean intensity from whole cells was measured at each time point and
normalized to the zero time point. Shown are the average results from three experiments 
 standard error. (E) Representation of the
FERM/kinase domain interface was created using Pymol and illustrates the key interaction between F596 in the kinase domain and a hydrophobic
pocket in the F2 subdomain of the FERM domain (17). (F) Normalized spectra of the FAK wild-type biosensor and a FAK biosensor with
mutations designed to disrupt the FERM/kinase domain interaction are shown. (G) Normalized FRET/CFP emission ratios of FAK biosensors
containing different mutations are shown. The constructs were analyzed as in panel C, and the FRET/CFP ratios of each were normalized to the
FRET/CFP ratio of the wild-type biosensor. Shown are the average results from at least three experiments 
 standard error. The results were
analyzed by one-way analysis of variance (P  0.0001) and Tukey’s multiple comparison post test (CYFAK413 versus each construct; P  0.001).
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upon the interaction between the FERM and catalytic domains
and that changes in FRET reflect changes in conformation.
Lysine 38 is a FERM domain residue that is required for the
interaction between the FERM and kinase domains (15).
Thus, it was surprising when the crystal structure of the auto-
inhibited FERM/catalytic domain complex revealed that K38
did not directly contact the catalytic domain. Instead, K38
appears to interact with acidic residues within the linker ex-
tending between the FERM and catalytic domains (32). To
further explore the role of K38 in FAK regulation, the K38A
mutation was introduced into the CYFAK413 biosensor. In-
terestingly, this mutant also showed a low FRET/CFP ratio
similar to that seen in CYFAK413 variants with mutations that
directly disrupt the FERM/catalytic domain interaction (Fig.
2G). This finding supports a role for K38 in stabilizing the
inactive conformation of FAK, perhaps through interactions
with the linker.
The biochemical characteristics of CYFAK413 were exam-
ined to determine if incorporation of the fluorescent probes
altered catalytic activity and if CYFAK413 was regulated in a
manner similar to wild-type FAK. The catalytic activity of
CYFAK413 was tested using an in vitro, immune complex
kinase assay. As shown in Fig. 3A, the kinase activity of
CYFAK413 was modestly higher than that of wild-type FAK,
presumably due to the insertion of citrine in the linker, since
CYFAK413 kinase activity was also higher than CFAK, which
has CFP fused to the N terminus of FAK. Notably, the activity
of CYFAK413 was much lower than the activated variant
CYFAK413-Y180A/M183A. To examine cell adhesion-depen-
dent regulation, cells expressing CYFAK413 or CFAK were
lysed and tyrosine phosphorylation was examined following
immunoprecipitation and Western blotting. Both CFAK and
CYFAK413 were phosphorylated on tyrosine in adherent cells
and exhibited reduced phosphotyrosine when cells were held
in suspension (Fig. 3B). Thus, tyrosine phosphorylation of
CYFAK413 was regulated by cell adhesion, similar to wild-type
FAK. In addition, the biochemical response of the biosensor to
lysophosphatidic acid (LPA) stimulation was measured to fur-
ther validate that this probe is regulated similar to wild-type
FAK. Following LPA stimulation, the biosensor exhibited in-
creased tyrosine phosphorylation (Fig. 3C). Despite a modest
increase in its catalytic activity, the fact that the biosensor was
regulated similarly to wild-type FAK in response to multiple
stimuli suggests that CYFAK413 is a suitable biosensor for
monitoring conformational changes in FAK in living cells.
Monitoring spatial regulation of FAK activity in living cells.
To monitor phosphorylation of tyrosine 397 in live cells, HeLa
cells transiently coexpressing CFAK and citrine-dSH2 were
plated onto fibronectin-coated coverslips and imaged by fluo-
rescence microscopy. Cells were illuminated with a CFP exci-
tation wavelength and the CFP and citrine (i.e., FRET) emis-
sions were captured. The FRETc/CFP ratio image is shown in
Fig. 4A. CFAK localized prominently to focal adhesions, al-
though there was also cytoplasmic localization. The distribu-
tion of FRET indicated that phosphorylation of FAK at ty-
rosine 397 occurs at focal adhesions. Importantly, CFAK-397F
exhibited a similar localization to CFAK, but there was no
FRET signal produced in cells coexpressing CFAK-397F and
citrine-dSH2. Expression levels of the wild-type and mutant
biosensors were comparable (Cai and Schaller, unpublished
data). The localization of FAK phosphorylated at tyrosine 397
to these sites was anticipated from studies using phospho-
specific antibodies for immunofluorescence and results using a
similar biosensor from Geiger’s laboratory (4, 46). Strikingly,
there appeared to be a heterogeneous distribution of phos-
phorylated FAK among the CFAK-positive focal adhesions
(Fig. 4A). A similar heterogeneous pattern of autophosphory-
lated FAK was observed by staining with a PY397 phospho-
specific antibody (Cai and Schaller, unpublished).
The current model of FAK regulation entails an autoinhibi-
tory interaction between the FERM and catalytic domains, and
thus activation requires a conformational change relieving this
inhibition. The development of the FAK conformational bio-
sensor allows a direct test of this model in living cells. HeLa
FIG. 3. Biochemical characterization of the FAK conformational
biosensor. (A) HEK293 cells expressing empty vector (Mock) or the
indicated FAK constructs were lysed and immunoprecipitated using a
FAK antibody. The immune complexes were incubated in an in vitro
kinase assay utilizing recombinant GST–paxillin–N-C3 as an exoge-
nous substrate. Phosphorylation of paxillin was detected using the
4G10 phosphotyrosine (P-Tyr) antibody. Equal amounts of substrate
were verified by blotting for paxillin using a polyclonal antiserum. FAK
in the immune complexes was verified by blotting for FAK. (B) The
wild-type and mutant biosensors were transiently expressed in HeLa
cells, and adherent cells (Ad) or cells incubated in suspension (Sus) at
37°C for 1 h were lysed. The biosensors were immunoprecipitated (IP)
using a GFP antibody and the immune complexes were analyzed by
Western blotting for phosphotyrosine (P-Tyr) using 4G10. Equal
amounts of FAK in the immune complexes were verified by blotting for
FAK. (C) HeLa cells expressing the FAK biosensor were serum
starved and stimulated with LPA (200 ng/ml) for 5 min. The biosensor
was immunoprecipitated from cell lysates and blotted with phospho-
tyrosine or a FAK antibody.
206 CAI ET AL. MOL. CELL. BIOL.
FIG. 4. (A) HeLa cells expressing the FAK autophosphorylation biosensor or the 397F control were trypsinized and plated on fibronectin-
coated coverslips. CFP, FRET, and citrine images were sequentially captured by fluorescence microscopy. CFP and FRETC/CFP ratio images of
the cells are shown. The ratio images are pseudocolored so that hotter colors reflect an increase in FAK autophosphorylation. Shown are
representative images (n  5 cells). The boxed area in the “CFAKCitrine-dSH2 FRETc/CFP” image is shown at higher magnification to the right.
(B) HeLa cells expressing the FAK biosensor or the constitutively active mutant were trypsinized and plated on fibronectin-coated coverslips. CFP,
FRET, and citrine images were sequentially captured by fluorescence microscopy. CFP and CFP/FRET ratio images of the cells are shown. Note
that the ratio images are pseudocolored so that hotter colors reflect an increase in the open, active conformation. Representative images are shown
(n  15 cells).
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cells transiently expressing CYFAK413 were plated onto fi-
bronectin-coated coverslips and analyzed by fluorescence
microscopy. Stimulation with the CFP excitation wavelength
produced emission of both a CFP and a citrine signal. A rep-
resentative CFP image and CFP/FRET ratio image are shown
in Fig. 4B. (Note that the ratio image shows the open confor-
mation as “hot” and the closed conformation as “cold.”) The
CFP/FRET ratio was elevated in focal adhesions, compared
with the ratio seen in the cytoplasm. As a control, the activated
variant CYFAK413-Y180A/M183A was analyzed in parallel.
The CFP/FRET ratio was high both in focal adhesions and in
the cytoplasm in cells expressing this control. Expression levels
of the wild-type and mutant biosensors were comparable (Cai
and Schaller, unpublished data). This result demonstrates that
the differences in CFP/FRET ratio in the CYFAK413-express-
ing cells were due to differences in conformation. The CFP/
FRET ratio in focal adhesions and in the adjacent cytoplasm
was quantified. In CYFAK413-Y180A/M183A-expressing
cells, this ratio was the same in focal adhesions and in the
cytoplasm (Fig. 5A). In CYFAK413-expressing cells, the CFP/
FRET ratio in focal adhesions was comparable to that seen in
CYFAK413-Y180A/M183A-expressing cells, but the cytoplas-
mic CFP/FRET ratio was significantly lower. These data dem-
onstrate that FAK exists in different conformations in different
regions of the cell. While it is not surprising that FAK is active
in focal adhesions, the CYFAK413 biosensor allows visualiza-
tion of conformation changes in live cells and thus provides
strong support for the current model of FAK regulation.
While conformationally active FAK was found in focal ad-
hesions, there was heterogeneity in the CFP/FRET ratio seen
in focal adhesions. This did not correlate with focal adhesion
size or amount of FAK in individual focal adhesions but rather
with location. FAK activity was higher in focal adhesions at the
cell margin compared with internal focal adhesions, and a
similar pattern was observed using the autophosphorylation
biosensor. This relationship was examined quantitatively by
plotting the minimal distance of each focal adhesion from the
cell margin versus the CFP/FRET and FRETc/CFP ratio of
the focal adhesion (Fig. 5B and C). This analysis supports the
hypothesis that there is a tendency of focal adhesions near the
periphery of the cell to have elevated levels of active/autophos-
phorylated FAK compared with focal adhesions further re-
moved from the cell margin. Interestingly, an asymmetric FAK
conformation spatial pattern was identified in many cells: i.e.,
FAK activation was elevated along one margin of the cell
relative to its activation at the opposite margin. These findings
suggest that FAK activity is regulated differentially in different
focal adhesions, which may play a role in the determination of
cell polarity and directional migration.
Temporal regulation of FAK conformation in living cells. To
study FAK conformation changes in response to soluble li-
gands, HeLa cells expressing the conformational biosensor
were serum starved and then stimulated with LPA. The aver-
age CFP/FRET ratio in the cell was determined over time and
was found to increase following stimulation (Fig. 5D). The
kinetics of conformation change in FAK paralleled the kinetics
of tyrosine phosphorylation of the biosensor (Fig. 5F). Stimu-
lation with PDGF produced a small, transient change in the
CFP/FRET ratio, while EGF stimulation did not produce a
change in FRET under these conditions. The CYFAK413-
Y180A/M183A constitutively active biosensor exhibited a con-
stant CFP/FRET ratio before and after stimulation with LPA
(Fig. 5E). These findings demonstrate that conformational
changes occur in FAK in response to soluble ligands.
A FERM domain basic patch is required for conformational
change. A basic patch in the F2 subdomain of the FERM
domain of FAK was identified as a key motif for FAK activa-
tion in vivo in response to cell adhesion and stimulation of the
Met receptor (14, 20). This motif is on the surface of the
FERM/catalytic domain complex and is close to the catalytic
domain interaction site in the crystal structure. Thus, this motif
is a potential site for controlling FAK conformational regula-
tion. To determine if this basic region was required for con-
formational regulation of FAK, alanine substitutions for basic
residues in this region were engineered into the conforma-
tional biosensor to create the K216A/K218A/R221A/K222A
mutant (KAKTLRK). The wild-type and mutant biosensors
were transiently expressed, and FRET was examined by flu-
orometric analysis. The mutant exhibited a higher FRET/CFP
ratio than the wild-type biosensor, suggesting that the integrity
of the basic patch was required for optimal induction of the
active conformation of FAK (Fig. 6A).
Acidic phospholipids bind the basic patch within the FAK
FERM domain. Given the basic nature of this region, potential
binding partners are likely to be acidic. Other FERM domains
exhibit high-affinity binding to PIP2 via positively charged mo-
tifs (23). The structure of the FAK FERM domain precludes
PIP2 binding via the precise mechanism utilized by other
FERM domains (9); however, an interaction via the basic
patch of the F2 subdomain remains a possibility. To examine
binding to PIP2, a fluorescence polarization assay was used.
Purified FERM domain was titrated into a solution of
BODIPY-labeled PIP2 containing C6-acyl chains, and aniso-
tropy was measured. Anisotropy was plotted against protein
FIG. 5. (A) Average CFP/FRET ratio of the cytoplasm or focal adhesions in HeLa cells expressing the wild-type biosensor or the constitutively
active variant (average of n  4 cells). The focal adhesion and cytoplasmic values were analyzed using an unpaired t test (, P  0.0005). (B and
C) The relationship between biosensor activity and focal adhesion location is shown. The distance of each focal adhesion from the cell margin is
plotted versus the average CFP/FRET or FRETC/CFP ratio, where the highest ratio has been normalized to 100%. Representative data from single
cells are shown (n  4). r, correlation coefficient. (D and E) HeLa cells expressing the FAK biosensor were serum starved and simulated with LPA
(200 ng/ml), EGF (50 ng/ml), or PDGF (50 ng/ml). CFP and FRET images were sequentially captured at 1-min intervals. The mean CFP/FRET
ratio of cells was calculated and normalized to the ratio at the time of stimulation. The change in the emission ratio of the FAK biosensor following
EGF, PDGF, or LPA stimulation is shown in panel A. The change in the emission ratio of the wild-type FAK biosensor is compared with that of
the constitutively active FAK biosensor mutant following LPA stimulation in panel B. Shown is the average response 
 standard error (n  3 cells).
(F) HeLa cells expressing the biosensor were stimulated with LPA and lysed at the indicated times. The biosensor was immunoprecipitated (IP)
and blotted with a phosphotyrosine (P-Tyr) antibody (top) or FAK antibody as a loading control (bottom).
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FIG. 6. Acidic phospholipids bind the basic patch within the FAK FERM domain. (A) Normalized FRET/CFP emission ratios of the wild-type
FAK biosensor and the basic patch mutant are shown. The mutant FRET/CFP ratio was normalized to FRET/CFP ratio of the wild-type biosensor.
Shown is a representative experiment (n  3). (B) The purified recombinant FERM domain was incubated with BODIPY-labeled phospholipids,
and binding was measured by fluorescence polarization. Anisotropy (mP, millipolarization units) is plotted against FERM domain concentration.
The average of three experiments 
 standard deviation is shown. (C) PE/PC vesicles containing increasing amounts of PIP2 were incubated with
a GST-FERM fusion protein. The vesicles were sedimented by centrifugation, and the amount of fusion protein in the vesicle containing pellet
(P) and the supernatant (S) was determined by SDS-PAGE and Coomassie blue staining. (D) PE/PC vesicles containing 10% (mass ratio) of the
indicated lipids were incubated with the GST-FERM fusion protein and analyzed as in panel A. Buf, buffer. (E) PE/PC vesicles containing PIP2
or phosphatidylinositol (PI) were incubated the wild-type GST-FERM domain or a basic patch mutant (KAKTLRK) and analyzed as in panel A.
(F and G) HeLa cells expressing a YFP-FERM domain fusion protein or the basic patch mutant (KAKTLRK) were fixed, permeabilized, and then
stained with rhodamine-phalloidin. Fixed cells were observed by laser-scanning confocal microscopy. (F) The percentages of cells containing the
YFP-FERM constructs in ruffles or at the membrane at the edge of the cell were scored. wt, wild type. Results represent the average from three
experiments 
 standard deviation with 100 cells counted per experiment. , P  0.005; , P  0.05. (G) Representative images of cells
expressing the YFP-FERM domain (two left panels) or the YFP-FERM KAKTLRK mutant (right panel) are shown. Arrows indicate YFP-FERM
localization in ruffles (left panel) and at the membrane at the periphery of the cell (middle panel).
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concentration, and the dissociation constant (Kd) was calcu-
lated (Fig. 6B). The Kd for PIP2 was 31.52 
 1.7 M, and that
for phosphatidylinositol was 200 M. The interaction of the
FERM domain with lipids was further validated using a vesicle
cosedimentation assay. PE/PC vesicles containing increasing
amounts of PIP2 were incubated with a GST-FERM fusion
protein. The vesicles were sedimented, and the amounts of
fusion protein in the vesicle-containing pellet and the super-
natant were determined by SDS-PAGE and Coomassie blue
staining. While the FERM domain bound poorly to PE/PC
vesicles, approximately 50% of the FERM domain bound to
vesicles containing 1% PIP2, and virtually all of the fusion
protein associated with vesicles containing 5% and 10% PIP2
(Fig. 6C). To further characterize lipid binding, the interaction
of the GST-FERM domain fusion protein with vesicles con-
taining other lipids was examined. Under conditions where the
protein was completely found in the pellet with PIP2-contain-
ing vesicles, GST-FERM associated weakly with phosphati-
dylinositol-containing vesicles (Fig. 6D). In contrast, the GST-
FERM fusion protein bound quite well to phosphatidylserine-
containing vesicles. Thus, the data suggest that the interaction
of GST-FERM with lipids is dictated by charge and that the
structure of the head group is less important for binding in
vitro.
The most likely lipid binding site on the FERM domain is
the F2 subdomain basic patch as it is the most basic feature of
the domain. To test its role in lipid binding, the KAKTLRK
mutations were engineered into the FERM domain. While the
wild-type GST-FERM domain associated strongly with PIP2-
containing vesicles, this mutant was defective for binding (Fig.
6E). If the FERM domain was capable of binding lipids in vivo
the domain might be recruited to the membrane. The FERM
domain of FAK was transiently expressed in HeLa cells as a
YFP fusion protein, and its localization was examined by con-
focal microscopy (Fig. 6G). The FERM domain partially co-
localized with F-actin in ruffles and was observed at the mem-
brane at the periphery of the cell. This pattern of localization
suggests that the FERM domain is capable of associating with
the membrane of the cell. Notably, KAKTLRK mutant exhib-
ited a cytoplasmic localization and was not frequently observed
in ruffles or at the membrane at the periphery of the cell (Fig.
6F). Expression of the wild-type and mutant FERM domains
was comparable (Cai and Schaller, unpublished). These data
suggest that the FAK FERM domain can interact with acidic
lipids in vitro and associate with the membrane in vivo, and the
basic patch on the F2 subdomain is required for both of these
activities.
PIP2-containing vesicles can activate FAK via conforma-
tional change. Given that the basic patch mutants are defective
for signaling in vivo and that this region can mediate binding to
PIP2-containing vesicles, it is possible that this interaction
might play a role in FAK activation. This was tested using a
recombinant fragment of FAK containing the FERM and cat-
alytic domains. The fragment adopts the inactive conformation
in which the Src phosphorylation sites within the activation
loop of FAK are protected from phosphorylation (32). The
FAK fragment was incubated with purified, active Src in lipid
vesicle binding buffer. Under these conditions, Src could
weakly induce FAK phosphorylation (Fig. 7A). Incubation of
the FAK fragment with PE/PC vesicles containing 10% PIP2
prior to phosphorylation by Src led to a dramatic increase in
phosphorylation of FAK, whereas incubation with PE/PC ves-
icles did not (Fig. 7A). As a control, phosphorylation of GST
fusion protein containing the activation loop peptide from
FIG. 7. (A) A recombinant fragment of FAK containing the
FERM and catalytic domains was incubated with Src (SH3 plus SH2
plus kinase) in the presence of the indicated liposomes in kinase
reaction buffer or in buffer alone (buf) for 30 min. As a control
substrate, a GST fusion protein containing a peptide mimicking the
activation loop of FAK was used. The reaction was terminated by the
addition of sample buffer, and phosphorylation of the substrates was
examined by Western blotting with a phosphotyrosine (P-Tyr) anti-
body. (B) The wild-type (WT) biosensor and the F2 basic patch mutant
biosensor (KAKTLRK) were coexpressed with PIP5KI or a catalyt-
ically defective mutant of PIP5KI (KD). The CFP/FRET ratio in
each case was determined by fluorometry. The average of three exper-
iments 
 standard error is shown. The emission ratios observed in the
presence of wild-type and catalytically inactive PIP5KI were analyzed
using an unpaired t test (, P  0.05). (C) The average CFP/FRET
ratio of the cytoplasm or focal adhesions in HeLa cells coexpressing
the wild-type biosensor and wild-type SopB or the catalytically inactive
mutant SopBcs is shown (average of n  6 cells 
 standard error). The
focal adhesion values in SopB- and SopBcs-expressing cells were an-
alyzed using an unpaired t test (, P  0.0025).
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FAK by Src was measured and did not change in the presence
or absence of PIP2-containing vesicles. These results are con-
sistent with the hypothesis that lipid vesicle binding leads to a
conformational change in FAK exposing the activation loop
for phosphorylation by Src.
Modulation of PIP2 regulates FAK conformation in vivo. To
determine if perturbation of PIP2 levels in vivo could alter
FAK activity, the conformational biosensor was used. To alter
PIP2 levels, type I phosphatidylinositol kinase  (PIPKI) was
coexpressed with the biosensor and the active state of the
biosensor compared with cells expressing the catalytically in-
active mutant of PIPKI. Coexpression with PIPKI resulted
in a higher CFP/FRET ratio (indicating an increase in acti-
vated FAK) than coexpression with the catalytically inactive
variant of the enzyme (Fig. 7B). These results demonstrate that
elevation of PIP2 levels in the cell promote the conversion of
FAK into its active conformation. Further, the basic patch in
the F2 subdomain of the FAK FERM domain is important for
this effect since the KAKTLRK mutant lacking the basic patch
was not responsive to altering the levels of PIP2 in the cell (Fig.
7B). To determine if PIP2 levels played a significant role in
regulating FAK conformation under physiological conditions,
SopB, an inositol polyphosphate 4-phosphatase, was coex-
pressed with the conformation biosensor and the effect upon
the biosensor in adherent cells was examined. The conforma-
tion of the biosensor in focal adhesions was compared with its
conformation in the cytoplasm by calculating the CFP/FRET
ratio, where a higher ratio reflects the active conformation and
a lower ratio reflects the inactive conformation (Fig. 7C). Ex-
pression of SopBcs, the catalytically inactive negative control,
had little effect upon FAK conformation. These cells exhibited
more activated FAK in focal adhesions than the cytoplasm,
similar to the results shown in Fig. 5A (Fig. 7C). In contrast,
SopB expression resulted in a decrease in activated FAK. In
these cells, the level of FAK activation in focal adhesions was
only slightly higher than the level of activation in the cyto-
plasm. These findings demonstrate that PIP2 depletion re-
duces FAK activation in focal adhesions, suggesting that PIP2
plays a role in regulating the conformation of FAK in cells
adherent to fibronectin.
DISCUSSION
The current model of FAK regulation evokes an intramo-
lecular autoinhibitory interaction between the N-terminal
FERM domain and central catalytic domain. Mutational and
biochemical studies support this hypothesis and the crystal
structure of the FERM/catalytic domain complex provides in-
sight into the mechanism of inhibition (15, 32). However, using
these technologies it is not possible to probe protein confor-
mation in vivo. FRET technology is a powerful tool to study
protein-protein interactions in living cells. As FRET efficiency
is dependent upon the distance between the two fluorophores
and their relative orientation, changes in FRET correspond to
changes in distance and orientation between the fluorescent
probes, and in the case of a single protein fused to two fluoro-
phores can reflect changes in conformation (35, 40, 43). Here,
we have developed genetically encoded FRET biosensors to
visualize changes in FAK conformation in vivo. These biosen-
sors have provided two important pieces of evidence in support
of the autoinhibitory model of FAK regulation. First, the anal-
ysis of the biosensors provides support for the crystal structure
of the FERM/catalytic domain complex. CFP is encoded at the
N terminus of FAK in these biosensors and citrine was inserted
at two different sites. Based upon the crystal structure, the
probe insertion sites in the CYFAK413 construct are approx-
imately 20 Å apart, and in the CYFAK700 construct the in-
sertion sites are predicted to be 70 Å apart. As predicted from
the structure, the former exhibited a high FRET signal and the
latter produced a weak FRET signal. Second, using the con-
formational biosensor, this study provides for the first time
direct evidence that a FAK conformational switch occurs in
vivo and is associated with FAK activation. In focal adhesions,
the probe exhibited an open conformation, whereas probes
located in the cytoplasm exhibited a closed conformation. This
is consistent with the body of literature implicating FAK as a
cell adhesion-regulated kinase and suggests that integrin sig-
naling contributes to the FAK conformational change. More-
over, another stimulus of FAK activation, LPA, induced a
change in the wild-type FAK biosensor conformation but had
no effect upon a mutant biosensor that is constitutively in the
open conformation. These findings demonstrate that multiple
stimuli regulate the conformation of FAK and that conforma-
tional change is a general mechanism leading to FAK activa-
tion.
Spatial regulation of FAK. The FAK biosensors provide
unique tools to investigate the spatial regulation of FAK. Cur-
rently, immunostaining using FAK phosphorylation-specific
antibodies is used for this purpose (46), but this approach has
some disadvantages. Antibody specificity is a potential prob-
lem that is often not well controlled. Further, tyrosine phos-
phorylation of FAK does not strictly correlate with catalytic
activity (50). It is impossible to probe FAK activity in live cells
using these approaches, and it is currently impossible to mon-
itor the conformation change of FAK by immunostaining.
The two biosensors report similar patterns of autophosphor-
ylation/conformational activation. Both indicate elevated au-
tophosphorylation/activation in peripheral focal adhesions
compared with internal focal adhesions. Interestingly, this pat-
tern is similar to the pattern of cell traction forces in spreading
cells (i.e., greatest traction forces at peripheral focal adhe-
sions) (3), which is consistent with a role for FAK in sensing
mechanical stimuli. In addition, results using both biosensors
indicate an asymmetry in autophosphorylation/activation of
FAK in polarized cells with the highest levels in areas of cell
protrusion. As FAK has been reported to regulate cell polarity
(55), this asymmetric activation pattern may define the direc-
tion of polarization.
FAK and lipid binding. The FERM domain of FAK was
shown to bind acidic phospholipids. PIP2 binding is a mecha-
nism of regulation of ezrin, radixin and moesin, but the mo-
lecular details of the interaction differ from FAK. In radixin,
the PIP2 headgroup associates with a basic pocket between the
F1 and F3 subdomains of the FERM domain, whereas the
corresponding site in FAK lacks the basic pocket (9, 23). Al-
though the F3 subdomain of FERM domains have a protein
fold similar to pleckstrin homology (PH) domains, the F3 sub-
domain of FAK cannot bind phospholipids since it lacks the
basic pocket that mediates the interaction of PH domains with
phospholipids. Instead, FAK appears to bind acidic phospho-
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lipids through surface-exposed basic residues at the tip of the
F2 subdomain. Not surprisingly, the FERM domain of FAK
binds PIP2 with lower affinity than PH domains. In contrast
with the 30 M Kd of the FERM domain, the PH domains of
phospholipase C- (PLC-) and SOS-1 are reported to bind
PIP2 with Kds of 2 M (PLC- and SOS-1) (26, 30, 31). The
affinity of the PH domain of spectrin ranges from 15 to 50 M,
depending upon buffer conditions (24). Thus, the affinity of the
FAK FERM domain for PIP2 is in the range of lower-affinity
PH domain interactions. It is also notable that there is prece-
dent for PIP2 binding to surface basic residues of proteins. For
example, PIP2 associates with the tail domain of vinculin
through surface basic residues rather than a discrete basic
pocket (2, 12).
The F2 basic patch is required for activation of FAK in
response to cell adhesion and following HGF stimulation (14,
20). This sequence binds acidic phospholipids, lipid vesicles
containing PIP2 alter the conformation of FAK in vitro, and
elevating PIP2 levels in cells results in alteration of the con-
formation of FAK in vivo. Further, reduction of PIP2 levels by
expression of SopB results in decreased activation of FAK in
focal adhesions in cells adherent to fibronectin. These findings
support the hypothesis that acidic phospholipids, including
PIP2, are physiologically relevant FAK FERM domain ligands
that regulate the release of autoinhibitory interactions allowing
FAK to adopt its active conformation. Additional evidence
from the literature demonstrates that acidic phospholipids are
important for the activation of FAK. Activation of FAK by
stimulation of some G protein-coupled receptors is apparently
blocked by depletion of PIP2 levels (34). Interestingly, a splice
variant of PIP5KI colocalizes with FAK at focal adhesions
and by localized generation of PIP2 might regulation FAK
function (19, 33). Other studies have suggested that the activity
of phosphatidylinositol 3-kinase is required for activation of
FAK in response to a number of different stimuli (7, 28, 36).
We hypothesize that these acidic phospholipids might regulate
FAK conformation through binding to the F2 basic patch.
Following HGF stimulation, this same sequence mediates
binding to tyrosine phosphorylated Met to facilitate FAK ac-
tivation (14). These results suggest the intriguing hypothesis
that a single site on the FERM domain of FAK can associate
with either acidic phospholipids or phosphopeptides to trigger
activation.
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